Retatrutide for renal insufficiency, chronic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Kidney Failure, Chronic

Why this status

  1. 7 Mar 2024: Trial registered, NCT06297603
  2. 15 Mar 2024: Trial started, NCT06297603

The trials

NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

State
Under way
Phase
Phase 3
People
341 taking part
Started
15 Mar 2024
Primary completion
26 Oct 2026
Arms
Retatrutide Dose 1, Retatrutide Dose 2, Retatrutide Dose 3
Results
None posted
  1. 7 Mar 2024: Trial registered
  2. 15 Mar 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Retatrutide (LY3437943).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.